RNA Atrium Therapeutics, Inc.companySEC Filings & Insider Trading Activity 2026
Latest Atrium Therapeutics, Inc. (RNA) SEC EDGAR filings in 2026 — including an 8-K current report filed on February 27, 2026. SignalX aggregates every new 10-K annual report, 10-Q quarterly report, 8-K current report, and Form 4 insider transaction for Atrium Therapeutics, Inc. (RNA) (SEC CIK 2093101), with AI-powered section-by-section summaries updated daily.
Latest 2026 SEC Filing Dates
AI 8-K Current Report AnalysisRecent 8-K Filings
Item 1.01: Entry into a Material Definitive Agreement
- • Transition Services Agreement signed Feb 26, 2026 between Atrium Therapeutics and Avidity — signals post-transaction integration phase underway
- • Avidity providing transition services to Atrium; Atrium providing only "nominal" services back — Avidity in dominant operational role
Item 5.01: Changes in Control of Registrant
- • Atrium Therapeutics completed spin-off from Avidity, becoming fully independent publicly traded company
- • Avidity retains zero ownership stake in Atrium post-distribution — clean separation with no residual control
Item 5.02: Departure/Appointment of Directors or Principal Officers
- • New equity incentive plan (2026 Incentive Award Plan) and ESPP adopted in connection with company's Separation and Distribution event
- • Plans govern how executives and directors will be compensated going forward — key for assessing future dilution risk
Item 7.01: Regulation FD Disclosure
- • Reg FD filing references a pending Acquisition described in a Registration Statement — deal completion timeline uncertain or at risk
- • No financial terms, deal size, or counterparty disclosed in this filing — investors must review the Registration Statement for deal specifics
Recent 8-K FilingsCurrent Reports
AI-powered analysis of Atrium Therapeutics, Inc. (RNA) 8-K current reports disclosing material events.
Frequently Asked Questions
What are the latest RNA SEC filings in 2026?
Atrium Therapeutics, Inc. (RNA) has filed an 8-K current report on February 27, 2026 with the SEC. SignalX tracks every new SEC EDGAR filing daily, including 10-K, 10-Q, 8-K, and Form 4 insider transactions, with AI-powered summaries of key sections.
What 8-K current reports has RNA filed recently?
Atrium Therapeutics, Inc. (RNA)'s most recent 8-K was filed on February 27, 2026. 8-K filings disclose material corporate events such as earnings releases, executive changes, mergers, and other significant developments. SignalX surfaces each 8-K with item-level summaries so you can quickly see what happened.
Where can I find RNA insider trading activity (Form 4)?
SignalX aggregates every RNA Form 4 insider transaction from SEC EDGAR. Form 4 reports show when officers, directors, and 10% shareholders buy or sell company stock, with transaction code, share count, and price per share.
How often does RNA file with the SEC?
Atrium Therapeutics, Inc. (RNA) files a 10-K annual report once per year (typically within 60 days of fiscal year-end) and 10-Q quarterly reports three times per year. 8-K current reports are filed as needed when material events occur, and Form 4 insider transaction reports are due within two business days of a trade. SignalX monitors SEC EDGAR daily to surface every new RNA filing with AI-powered analysis.
What is the difference between 10-K, 10-Q, and 8-K SEC filings?
A 10-K is a comprehensive annual report with audited financials, business overview, and risk factors. A 10-Q is a shorter quarterly report with unaudited financials and management discussion. An 8-K is a current report filed when a material event occurs — such as earnings releases, executive changes, acquisitions, or other significant developments. SignalX provides AI-generated summaries for all three filing types for Atrium Therapeutics, Inc. (RNA).
What is RNA's SEC CIK number?
Atrium Therapeutics, Inc. (RNA)'s SEC CIK (Central Index Key) number is 2093101. The CIK is a unique identifier assigned by the SEC to every filing entity. You can use CIK 2093101 to look up all RNA filings on SEC EDGAR, or browse them here on SignalX with AI-powered analysis.
Where can I find RNA return on equity (ROE) and financial data?
SignalX extracts XBRL financial data from Atrium Therapeutics, Inc. (RNA) 10-K annual filings, including revenue, net income, gross profit, operating income, EPS, total assets, stockholders' equity, and operating cash flow. Return on equity (ROE) can be derived from net income divided by stockholders' equity. Multi-year financial trends are displayed in the Financial Summary table above.
Stay on top of Atrium Therapeutics, Inc. SEC filings
Insider trading data, fund holdings, cross-signal detection, and AI-powered analysis for 2+ filings.